Dual‐photon microscopy‐based quantitation of fibrosis‐related parameters (q‐FP) to model disease progression in steatohepatitis

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Hepatology

• Publication date

  2017-06-01

• Fields of study

  Medicine, Environmental Science

• Identifiers
  DOI 10.1002/hep.29090PMID 28133774PMCID PMC5444965
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Regulatory Science and Drug Approval for Alcoholic and Nonalcoholic Steatohepatitis.

  2016influential reference
• End Points Must Be Clinically Meaningful for Drug Development in Nonalcoholic Fatty Liver Disease.

  2016influential reference
• MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice.

  2016cited by this paper
• Automated quantitation of cirrhotic patterns showing the excellent accuracy in reflecting the pathophysiologic evolution and disease severity in cirrhotic animal model and chronic hepatitis B liver biopsies.

  2016cited by this paper
• Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood

  2016cited by this paper
• Data-driven desirability function to measure patients’ disease progression in a longitudinal study

  2016cited by this paper
• Nonalcoholic Fatty Liver Disease: Pros and Cons of Histologic Systems of Evaluation

  2016cited by this paper
• Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.

  2015cited by this paper
• Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases–U.S. Food and Drug Administration Joint Workshop

  2015cited by this paper
• Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.

  2015cited by this paper
• Automated biphasic morphological assessment of hepatitis B-related liver fibrosis using second harmonic generation microscopy

  2015cited by this paper
• qFibrosis: a fully-quantitative innovative method incorporating histological features to facilitate accurate fibrosis scoring in animal model and chronic hepatitis B patients.

  2014influential reference
• A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis

  2012cited by this paper
• Nonalcoholic Fatty Liver Disease: What the Pathologist Can Tell the Clinician

  2012cited by this paper
• The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

  2012influential reference
• Corrigendum:The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

  2012cited by this paper
• Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States.

  2011cited by this paper
• Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver‐related mortality

  2011cited by this paper
• Experimental design and desirability function approach for development of novel anticancer nanocarrier delivery systems.

  2011cited by this paper
• Fibrillar collagen scoring by second harmonic microscopy: a new tool in the assessment of liver fibrosis.

  2010cited by this paper
• Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.

  2010cited by this paper
• Use of desirability functions to evaluate health status in patients with cirrhosis.

  2010cited by this paper
• Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease.

  2009cited by this paper
• Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease.

  2009cited by this paper
• Diagnosis of hepatic steatosis and fibrosis by transient elastography in asymptomatic healthy individuals: a prospective study of living related potential liver donors

  2007cited by this paper
• Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction.

  2007cited by this paper
• Design and validation of a histological scoring system for nonalcoholic fatty liver disease

  2005influential reference
• Sampling variability of liver fibrosis in chronic hepatitis C

  2003cited by this paper
• An assessment of digital image analysis to measure fibrosis in liver biopsy specimens of patients with chronic hepatitis C.

  2000cited by this paper
• Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations.

  1998cited by this paper
• American Association for the Study of Liver Diseases

  1959cited by this paper

• AI-assisted fibrosis scoring in MASH: Exploring pathologist decision-making with an SHG-based AI digital pathology tool

  2026cites this paper
• Liver fibrosis progression analyzed with AI predicts renal decline

  2025cites this paper
• The Relationship Between Non-Invasive Tests and Digital Pathology for Quantifying Liver Fibrosis in MASLD

  2025cites this paper
• Artificial Intelligence in Liver Pathology: Precision Histology for Accurate Diagnoses.

  2025cites this paper
• Development of AI Based Fibrosis Detection Algorithm by SHG/TPEF Microscopy for Fully Quantified Liver Fibrosis Assessment in MASH

  2025cites this paper
• Aramchol improves hepatic fibrosis in metabolic dysfunction–associated steatohepatitis: Results of multimodality assessment using both conventional and digital pathology

  2024cites this paper
• Utility of AI digital pathology as an aid for pathologists scoring fibrosis in MASH.

  2024cites this paper
• Digital quantitation of bridging fibrosis and septa reveals changes in natural history and treatment not seen with conventional histology

  2024cites this paper
• Automated quantitative assay of fibrosis characteristics in tuberculosis granulomas

  2024cites this paper
• Collagen co-localised with macrovesicular steatosis for fibrosis progression in non-alcoholic fatty liver disease

  2023cites this paper
• Digital pathology and artificial intelligence in non-alcoholic steatohepatitis: current status and future directions.

  2023cites this paper
• Digital pathology for nonalcoholic steatohepatitis assessment

  2023cites this paper
• Collagen co-localized with macrovesicular steatosis better differentiates fibrosis progression in non-alcoholic fatty liver disease mouse models

  2023cites this paper
• Second-Harmonic Generated Quantifiable Fibrosis Parameters Provide Signatures for Disease Progression and Regression in Nonalcoholic Fatty Liver Disease

  2023cites this paper
• The role of altered lipid composition and distribution in liver fibrosis revealed by multimodal nonlinear optical microscopy

  2023cites this paper
• Efficacy and Safety of a Botanical Formula Fuzheng Huayu for Hepatic Fibrosis in Patients with CHC: Results of a Phase 2 Clinical Trial

  2022cites this paper
• Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD.

  2022cites this paper
• The miR-23b/27b/24-1 Cluster Inhibits Hepatic Fibrosis by Inactivating Hepatic Stellate Cells

  2022cites this paper
• Histological assessment based on liver biopsy: the value and challenges in NASH drug development

  2022cites this paper
• Breakthroughs in therapies for NASH and remaining challenges.

  2022cites this paper
• Upregulation of GLT25D1 in Hepatic Stellate Cells Promotes Liver Fibrosis via the TGF-β1/SMAD3 Pathway In Vivo and In vitro

  2022cites this paper
• Developing a New qFIBS Model Assessing Histological Features in Pediatric Patients With Non-alcoholic Steatohepatitis

  2022cites this paper
• Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH.

  2022cites this paper
• Non-alcoholic fatty liver disease: the pathologist’s perspective

  2022cites this paper
• Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis

  2022cites this paper
• Second-harmonic generation (SHG) microscopy and hepatic venous pressure gradient-based validation of a novel histological staging system for alcoholic hepatitis

  2021cites this paper
• Improved second harmonic generation and two-photon excitation fluorescence microscopy-based quantitative assessments of liver fibrosis through auto-correction and optimal sampling.

  2021cites this paper
• Current status and challenges in the drug treatment for fibrotic nonalcoholic steatohepatitis

  2021cites this paper
• Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH)

  2021cites this paper
• BMS‐986263 in patients with advanced hepatic fibrosis: 36‐week results from a randomized, placebo‐controlled phase 2 trial

  2021cites this paper
• Reliable computational quantification of liver fibrosis is compromised by inherent staining variation

  2021cites this paper
• Prospects for a better diagnosis and prognosis of NAFLD: a pathologist´s view

  2021cites this paper
• qFIBS: An Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis

  2020influential citation
• Improved quantitative assessment of HBV-associated liver fibrosis using second-harmonic generation microscopy with feature selection.

  2020cites this paper
• Consensus on the diagnosis and treatment of hepatic fibrosis (2019)

  2020cites this paper
• Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective

  2020influential citation
• Long-term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis.

  2020cites this paper
• Quantifying and monitoring fibrosis in non-alcoholic fatty liver disease using dual-photon microscopy

  2019cites this paper
• Quantification of hepatic steatosis in chronic liver disease using novel automated method of second harmonic generation and two-photon excited fluorescence

  2019cites this paper
• Comparing hepatic steatosis distribution patterns between non-alcoholic fatty liver disease and fatty liver disease with chronic hepatitis B by second-harmonic generation/two-photon excited fluorescence method.

  2019cites this paper
• Progression and regression of fibrosis in viral hepatitis in the treatment era: the Beijing classification

  2018cites this paper
• Determinants of fibrosis progression and regression in NASH.

  2018cites this paper
• Improved performance of quantitative collagen parameters versus standard histology in longitudinal assessment of nonadvanced liver fibrosis for chronic hepatitis B

  2018cites this paper
• Second harmonic generation microscopy provides accurate automated staging of liver fibrosis in patients with non-alcoholic fatty liver disease

  2018cites this paper
• Obeticholic Acid Modulates Serum Metabolites and Gene Signatures Characteristic of Human NASH and Attenuates Inflammation and Fibrosis Progression in Ldlr‐/‐.Leiden Mice

  2018cites this paper
• Dual photon microscopy based quantitation of fibrosis‐related parameters (q‐FP) to model disease progression in steatohepatitis: Methodological issues

  2017cites this paper
• Comments on “Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis”

  2017cites this paper
• Comments on “Increased Risk of Mortality by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: Systematic Review Meta-Analysis”

  2017cites this paper
• Second Harmonic Generation Reveals Subtle Fibrosis Differences in Adult and Pediatric Nonalcoholic Fatty Liver Disease

  2017cites this paper
• Reply

  2017cites this paper
• Autofluorescence Label-Free Imaging of the Liver Reticular Structure.

  year unknowncites this paper